Connect with us

Biotech firm working on Covid-19 vaccine raises $20 million

February 15, 2021 - Oragenics Inc., a Tampa biotech company that’s working on a Covid-19 vaccine, has raised $20 million via sale of stock that was facilitated by Alliance Global Partners, a New York investment and advisory firm. The company also received $1.9 million from the exercise of common stock warrants. According to a press release, Oragenics has given a notice for the redemption of all outstanding shares of the company’s Series C, non-convertible, preferred stock, which President and CEO Alan Joslyn said will raise an additional $5.6 million. “We are delighted that we were able to raise capital to fund our operations through a number of anticipated key value-creating milestones towards the initiation of the Phase 2 clinical trial of our SARS CoV-2 vaccine, Terra CoV-2,” Joslyn stated in the release.

More Zaps Frontpage

The St. Pete Catalyst

The Catalyst honors its name by aggregating & curating the sparks that propel the St Pete engine.  It is a modern news platform, powered by community sourced content and augmented with directed coverage.  Bring your news, your perspective and your spark to the St Pete Catalyst and take your seat at the table.

Email us: spark@stpetecatalyst.com

Subscribe for Free

Share with friend

Enter the details of the person you want to share this article with.